Felicia L. Wilson, M.D.

18-260 - ARST1431 - Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaStatus: open

ARST1431 A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Treatment for Pediatric Oncology- Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

19-256 - AALL1731 - A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL TherapyStatus: open

AALL1731 A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Treatment for Pediatric Oncology- Localized B-Lymphoblastic Lymphoma (B-LLy)

Mitchell Cancer Institute

1660 Spring Hill Avenue Mobile, Alabama 36604

19-452 - AALL1732 - Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyStatus: open

Treatment for Pediatric Oncology- Localized B-Lymphoblastic Lymphoma (B-LLy)

Pediatrics Complex Care Clinic

1601 Center Street
Suite 1A
Mobile, Alabama 36604

20-037 - Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin LymphomaStatus: open

S1826 - A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Treatment for Pediatric Oncology - Classical Hodgkin Lymphoma

20-182 - ACNS1721 - Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 MutationsStatus: open

ACNS1721: A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations

Treatment for Pediatric Oncology - Brain tumor

20-206 - Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven MedulloblastomaStatus: open

ACNS1422-A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Treatment for Pediatric Oncology - Medulloblastoma